Eli Lilly and Novo Nordisk are facing market share losses in the GLP-1 sector, with trading taking place in Copenhagen's capital market.
4 reports, 3 independent
Updated Sep 28
Gone quiet
- Reports
- 4
- Developments
- 1
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Eli Lilly and Novo Nordisk are facing market share losses in the GLP-1 sector, with trading taking place in Copenhagen's capital market.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Eli Lilly and Novo Nordisk are competing for market share in the weight loss drug sector.Also in this story
- Eli Lilly captured market share from Novo Nordisk in the weight loss drug sector.
- New competing products are launching in the weight-loss market, intensifying the competition between Eli Lilly and its rivals.
- Eli Lilly and Novo Nordisk are competing for market share in the weight loss drug sector, seeking Australian regulatory approval.
The entities involved
-
Eli Lilly and Company
American pharmaceutical company
-
Novo Nordisk
Danish pharmaceutical company